One shot instead of two, and broader protection for those at highest risk.
Em um passo que reflete a busca contínua da medicina por proteção mais ampla contra doenças antigas, o Brasil autorizou uma vacina pneumocócica capaz de cobrir vinte cepas distintas — o dobro do padrão anterior. A Anvisa aprovou a Prevenar 20, da Pfizer, em dezembro de 2023, abrindo caminho para que crianças pequenas, idosos e imunossuprimidos recebam uma cobertura mais completa contra pneumonia, meningite e infecções graves. O que resta agora não é uma questão científica, mas uma questão de acesso: o preço ainda precisa ser regulado antes que a vacina chegue às mãos de quem mais precisa.
- Sessenta por cento dos casos invasivos de pneumococo em crianças brasileiras são causados por apenas três das sete cepas recém-incorporadas — uma lacuna de proteção que a nova vacina agora fecha.
- Idosos acima de 60 anos precisavam tomar duas vacinas diferentes em sequência; a Prevenar 20 elimina essa etapa dupla com uma dose única.
- A aprovação pela Anvisa foi publicada no Diário Oficial em 18 de dezembro, mas a vacina ainda não pode ser comercializada até que a câmara de regulação de preços conclua sua análise em até 90 dias.
- A expectativa é que o imunizante chegue às farmácias até o fim do primeiro trimestre de 2024, seguindo caminho já aberto pela aprovação do FDA nos Estados Unidos em abril do mesmo ano.
- Os efeitos colaterais são leves e passageiros — dor local, vermelhidão e febre baixa — sem contraindicações além de alergia grave a seus componentes.
A Anvisa aprovou nesta semana a Prevenar 20, vacina da Pfizer contra vinte tipos de pneumococo — sete a mais do que a versão anterior de treze cepas atualmente em uso no Brasil. A publicação no Diário Oficial ocorreu na segunda-feira, 18 de dezembro.
A doença pneumocócica, causada pela bactéria Streptococcus pneumoniae, pode evoluir rapidamente para pneumonia, meningite ou infecções no sangue, transmitindo-se pelo ar em gotículas de saliva. A nova vacina cobre vinte sorotipos específicos e é indicada a partir das seis semanas de vida, com foco especial em crianças menores de cinco anos, adultos acima de 60 e pessoas com condições que comprometem a imunidade, como HIV, diabetes e transplantes.
Para os idosos, o ganho prático é imediato: o esquema atual exige duas vacinas aplicadas em momentos distintos para ampliar a cobertura. A Prevenar 20 unifica essa proteção em uma única dose. Flávia Bravo, diretora da sociedade brasileira de imunizações, destaca que três das novas cepas incluídas são responsáveis por cerca de 60% dos casos invasivos em crianças no país — tornando a ampliação especialmente relevante para o contexto epidemiológico brasileiro.
Antes de chegar às farmácias, a vacina precisa passar pela regulação de preços: a Pfizer submeterá sua proposta à câmara regulatória, que tem 90 dias para deliberar. A previsão é que o imunizante esteja disponível comercialmente até o final do primeiro trimestre de 2024. Os Estados Unidos já haviam aprovado a mesma vacina pela FDA em abril deste ano.
Os efeitos adversos são brandos — dor e vermelhidão no local da aplicação, eventualmente febre baixa — e passam rapidamente com analgésicos e compressas frias. A aprovação representa um avanço concreto na proteção pneumocócica no Brasil; o próximo desafio é garantir que o processo de precificação não atrase o acesso para as populações mais vulneráveis.
Brazil's health regulator gave the green light this week to a new pneumococcal vaccine that covers twice as many disease-causing strains as the current standard. Anvisa, the country's drug and medical device authority, approved Prevenar 20, a shot made by Pfizer that protects against twenty different types of pneumococcus bacteria. The approval was published in the official government gazette on Monday, December 18th.
The vaccine addresses a real gap in protection. Pneumococcal disease—caused by the bacterium Streptococcus pneumoniae—can turn serious fast, triggering pneumonia, meningitis, or blood infections. It spreads the way most respiratory illnesses do: through saliva droplets when someone coughs, sneezes, or talks. The new vaccine guards against strains numbered 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Seven of those strains are entirely new to the vaccine lineup; the other thirteen were already part of Prevenar 13, the thirteen-valent version currently in use.
The practical benefit is significant for older adults. Right now, doctors recommend a two-step approach for people over sixty: first a dose of the thirteen-valent vaccine, then later a dose of the twenty-three-valent version to fill in the gaps. Prevenar 20 collapses that into a single shot, eliminating the need for sequential vaccination. For children under five and for people of any age living with conditions that weaken immunity—HIV infection, organ transplant, diabetes, obesity, and others on a long list—the new vaccine offers broader protection against the strains most likely to cause severe disease.
Flávia Bravo, director of Brazil's immunization society, points out that three of the newly added strains are particularly important for the Brazilian context. Current disease surveillance data shows that roughly sixty percent of invasive pneumococcal cases in children are caused by those three specific types. The expanded formula reaches beyond those frequent culprits to cover less common but still dangerous strains, and it addresses gaps in protection for elderly patients as well. The vaccine is licensed for use starting at six weeks of age.
Before Prevenar 20 reaches pharmacy shelves, it has to clear one more hurdle: price regulation. Pfizer will submit its pricing proposal to Brazil's pharmaceutical pricing board, which has ninety days to set the approved price. Bravo expects the vaccine to be commercially available by the end of the first quarter of 2024. The United States approved the same vaccine through the FDA back in April of this year.
As for side effects, they are mild and temporary. People typically experience soreness at the injection site—pneumococcal vaccines tend to be a bit more painful than some others—along with possible swelling, redness, and sometimes a low fever. None of these effects leave lasting damage. A fever reducer and a cold compress usually handle any discomfort. The vaccine should not be given to anyone with a severe allergic reaction to any of its components or to diphtheria toxoid.
The approval marks a significant step forward for pneumococcal protection in Brazil, particularly for the groups most vulnerable to serious disease. The question now is how quickly the pricing process moves and whether the vaccine becomes accessible to those who need it most.
Notable Quotes
About 60% of invasive pneumococcal cases in Brazilian children involve strains the older vaccine didn't cover, making the three newly added types particularly important for the country.— Flávia Bravo, director of Brazil's immunization society
For elderly patients, the 20-valent vaccine eliminates the need for sequential vaccination—one dose replaces the previous two-shot approach.— Flávia Bravo, director of Brazil's immunization society
The Hearth Conversation Another angle on the story
Why does Brazil need a new pneumococcal vaccine when there's already one in use?
The existing thirteen-valent vaccine covers the most common strains causing severe disease in children, but it leaves gaps—especially for older adults. The new twenty-valent version adds seven additional strains and simplifies how we vaccinate elderly people, moving from two shots to one.
Who actually needs this vaccine?
Children under five, adults over sixty, and anyone younger with conditions that compromise immunity—HIV, transplant recipients, diabetics, obese individuals. For healthy people between five and sixty, the risk of severe pneumococcal disease is low enough that routine vaccination isn't recommended.
What makes those seven new strains important?
They're less frequent than the ones already covered, but they matter. In Brazil's current disease surveillance, about sixty percent of invasive pneumococcal cases in children involve strains the old vaccine didn't cover. The new vaccine extends protection to those cases and also addresses what's circulating in older populations.
How long until Brazilians can actually get it?
There's a regulatory step first. Pfizer has to propose a price, and the government's pricing board has ninety days to approve it. If that moves smoothly, the vaccine should be available by the end of March 2024.
Are there side effects people should worry about?
No. Soreness at the injection site, some swelling or redness, maybe a fever. All temporary, all manageable with a fever reducer and a cold compress. Pneumococcal vaccines tend to be slightly more uncomfortable than some others, but that's the extent of it.
Why did the U.S. approve this first?
The FDA cleared it in April. Brazil's approval now puts the country in line with that decision, but the real work is the pricing negotiation. That's what determines when people can actually access it.